Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Request for Proposals: Ann Theodore Foundation Sarcoidosis Inhibitor of mTOR (SIM) Trial

Milken Institute

The Ann Theodore Foundation (ATF) is launching a new funding program to support the study of repurposed mechanistic target of rapamycin (mTOR) inhibitors as treatments for cutaneous sarcoidosis. This program will be executed in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC).

The ATF Sarcoidosis Inhibitor of mTOR (SIM) Trial is now accepting applications for two-year investigator-initiated clinical trials that will test the efficacy of mTOR inhibitors in treating cutaneous sarcoidosis. This trial would be considered an early Phase 2 trial and would provide scientific support for a future Phase 2b/3 or a Phase 3 trial. ATF will fund this trial, and SPARC will operate as program administrators.

The ATF SIM Trial will award one two-year investigator-initiated clinical trial grant led by established, independent investigators at qualifying research-based organizations around the world. The awarded team will be eligible for up to US$250,000 in funding for direct costs per year plus 15 percent in indirect costs, totaling US$287,500 per year for a total of US$575,000 over two years. Applications that define the trial population to appropriately power the trial and demonstrate a history or capacity to fully enroll during the grant period, including clinical trial networks and consortia, will be prioritized.

Deadline: April 20, 2026

Specialties

Medical

Medical - Clinical Science

Medical - Basic Science

Eligibility Requirements

Each applicant organization may be:
1. a nonprofit academic or research organization, including domestic and non-US nonprofit organizations and domestic and non-US public/private academic universities or organizations of higher learning (including colleges, universities, medical schools, and other related academic research organizations)
2. a certain qualified governmental agency with active biomedical research programs
3. a for-profit organization, including pharmaceutical companies
Successful applicants must agree to and adhere to the ATF open science policy (see Grant Terms #10 below). Applications from established consortia or clinical trial networks will be prioritized.
All proposed research projects must be led by a principal investigator (PI) who holds a doctorate (e.g., PhD, MD) or a related degree. The PI must be an independent investigator.

Sponsor Details

Sponsor Institute/Organizations: Milken Institute

Sponsor Type:

Address: 950 New Hampshire Avenue, NW

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity